PHARMING GRP SP. ADRS (PHG) — Defensive Interval Ratio

Latest as of December 2025: 238 days

PHARMING GRP SP. ADRS (PHG) has a Defensive Interval Ratio of 238 days as of December 2025. Defensive assets of €75.56 Million (cash €-, short-term investments €33.80 Million, receivables €41.77 Million) cover 238 days of daily cash needs of €317.24K/day. Check PHARMING GRP SP. ADRS tangible net worth ratio to evaluate the tangible quality of the company's equity base.

Defensive Interval Ratio

238 days
Days of operational coverage

Defensive Assets

€75.56 Million
Cash + ST Investments + Receivables

Daily Cash Need

€317.24K
Current Liabilities ÷ 365

Current Liabilities

€115.79 Million
EUR

PHARMING GRP SP. ADRS Defensive Interval Ratio (2021–2025)

This chart shows how PHARMING GRP SP. ADRS's Defensive Interval Ratio has evolved across 5 annual periods from 2021 to 2025. As of December 2025, the ratio stands at 238 days, meaning defensive assets of €75.56 Million can fund 238 days of operations without new revenue. Also explore PHARMING GRP SP. ADRS annual equity growth to track the company's year-over-year net asset growth rate.

Annual Defensive Interval Ratio for PHARMING GRP SP. ADRS (2021–2025)

The table below presents the year-by-year Defensive Interval Ratio for PHARMING GRP SP. ADRS from 2021 to 2025, covering 5 annual filings. Each row shows defensive assets, daily cash need, the DIR in days, and the change in days compared to the prior year. For live market cap and the full company financial profile, see PHG market cap.

Year DIR (days) Defensive Assets (EUR) Daily Cash Need Cash ST Investments Change (days)
2025 238 days €75.56 Million €317.24K/day €- €33.80 Million ▼ -526 days
2024 764 days €154.48 Million €202.20K/day €- €112.95 Million ▼ -112 days
2023 876 days €187.09 Million €213.61K/day €- €151.68 Million ▲ +748 days
2022 128 days €20.96 Million €163.56K/day €- €0.00 ▼ -13 days
2021 141 days €18.08 Million €128.14K/day €- €-
DIR = (Cash + Short-term Investments + Net Receivables) / (Daily Cash Expenses)